Neoadjuvant Therapy Followed by Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Pancreatic Cancer

  • participants needed
  • sponsor
    University of Alabama at Birmingham
Updated on 8 November 2020
platelet count
measurable disease
karnofsky performance status
neutrophil count
cancer chemotherapy
pancreatic neoplasm


The purpose of this study is to evaluate a new treatment routine for patients with borderline resectable and unresectable pancreas cancers.


We want to find out what effects, good and bad, using chemotherapy combinations modified FOLFIRINOX (Oxaliplatin, Irinotecan, and fluorouracil) OR gemcitabine plus nab-paclitaxel (Gem-ABRAXANE) and radiation using Stereotactic Body Radiation Therapy (SBRT) have on the cancer and to increase the percentage of patients who can have surgery to remove their disease. SBRT is a short course of high dose precisely delivered radiation. The two combination chemotherapy routines (mFOLFIRINOX or GEM-ABRAXANE) have been shown in previous clinical trials to be the most effective FDA approved chemotherapy in wide spread pancreatic cancers. These chemotherapy drugs will be given before the surgery. Radiation Therapy, using the 5 week method as well as SBRT has been used as standard of care and found to be effective to reduce the size of pancreatic cancer, so patients can have surgery.

SBRT uses advance techniques to deliver radiation therapy which minimizes the volume of normal tissue receiving high dose radiation while maximizing the dose to the tumor. The use of SBRT spares normal tissue and reduces the side effects of radiation. By being more precise, and using a higher dose of radiation per treatment, the radiation delivery time can be decreased to about one week. When this chemotherapy followed by SBRT is combined in this order, this routine has the potential to treat both the primary disease, as well as to prevent the early spread of disease. It is hoped that the treatment routines in this study will increase the percentage of patients who can proceed to have surgery to remove their tumor.

This combination of chemotherapy drugs, mFOLFIRINOX or GEM-ABRAXANE and the sequence of chemotherapy followed by SBRT- the shorter course of radiation has not been studied previously and is considered investigational.

Condition Pancreatic Cancer
Treatment FOLFIRINOX Drugs, Gemcitabine-nab Paclitaxel
Clinical Study IdentifierNCT03641183
SponsorUniversity of Alabama at Birmingham
Last Modified on8 November 2020


Yes No Not Sure

Inclusion Criteria

Histologically or cytologically proven adenocarcinoma of the pancreas. Patients with mixed tumor with predominant adenocarcinoma pathology can be enrolled
Subjects will be staged according to the 2010 American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-4, being eligible; and have a primary tumor of the pancreas (either pancreatic head, neck, uncinate process, or body/tail)
The tumor must be deemed as being borderline/unresectable. Final CT confirmation of surgical staging/eligibility will be at the discretion of the pancreatic surgeon of the patient
Disease must be confined to loco-regional site as confirmed by CT imaging and / or diagnostic staging laparoscopy to avoid occult peritoneal deposits Diagnostic laparoscopy will be performed only if absolutely required
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) on imaging studies CT
Karnofsky performance status greater than or equal to 70 or Eastern Cooperative Oncology Group (ECOG) performance of 0-2
Age > 18
Estimated life expectance > 12 weeks
If female patient is of child bearing potential, she must have a negative serum pregnancy test (hCG) documented up to 72hrs prior to administration of first study drug
Patient has screening blood work performed which includes the following (should be drawn 14 days prior to enrollment)
Absolute neutrophil count (ANC) > 1.5 x 109/L
Platelet count 100000/mm3
Hemoglobin (HgB) 9g/dL
Aspartate aminotransferase (AST), Alanine Aminotransferase (ALT) 2.5 x upper limit of normal (ULN) Total Bilirubin 1.5 ULN
Serum Cr within normal limits (WNL)
Prothrombin Time and International Normalized Ratio (PT/INR) and Partial Thromboplastin Time (PTT) within normal limits (15%)
Disease must be encompassed in a reasonable SBRT "portal" as defined by the treating radiation oncologist

Exclusion Criteria

Ineligible Histology including non-adenocarcinomas, adenosquamous carcinoma, islet cell carcinomas, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct and ampullary carcinomas
Patients must not have received prior pancreatic surgery, radiation therapy, chemotherapy or any investigational therapy for pancreatic cancer
Patients with tumors extending or invading duodenum or gastric are not eligible
Evidence of distant metastasis on upright chest x-ray, CT or other staging studies
Subjects with recurrent disease are not eligible
Prior radiation therapy to the upper abdomen or liver at the discretion of the treating radiation oncologist could impair delivery of the prescribed radiation treatment
Patients with scleroderma, ulcerative colitis or other systemic conditions deemed risky for radiation treatment. Therefore, will be excluded
Prior chemotherapy
Subjects in their reproductive age who are breast feeding or have a positive pregnancy test
Any co-morbid condition such as but not limited to congestive heart failure, cardiac arrhythmia or psychiatric illness of sufficient severity to limit full compliance with the protocol per assessment by the individual treating physician
Concurrent active infection
No prior malignancy allowed except cervical cancer in situ, adequately treated basal cell or squamous cell carcinoma of skin or treated low risk prostate cancer
Patient with known historical or active infection with HIV, Hepatitis B or Hepatitis C
Patient who has undergone recent major surgery, other than diagnostic prior to enrollment
Patient who has a history of allergy or hypersensitivity to any of the study drugs
Patients with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, interstitial pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies
Patients with greater than grade 2 peripheral neuropathy at the time of enrollment are not eligible
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note